Jacobs & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Jacobs & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,330	Closed	-$279K	–	126
2015 Q2	$279K	Hold	3,330	–	–	0.07%	115
2015 Q1	$250K	Buy	+3,330	New	+$233K	0.06%	116

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jacobs & Co's XBI Position: Q3 2015 in Review

Jacobs & Co sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2015, closing a stake of 3,330 shares — an estimated $279K sold.

Jacobs & Co first reported a position in XBI in Q1 2015 and held it in 2 quarters. The position peaked at $279K in Q2 2015. 196 funds tracked by Wall St. Rank hold XBI as of Q3 2015.

Jacobs & Co reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2015 after selling out during the quarter.
Jacobs & Co sold 3,330 State Street SPDR S&P Biotech ETF shares in Q3 2015, an estimated $279K.
Jacobs & Co first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and held it in 2 quarters.
Jacobs & Co's State Street SPDR S&P Biotech ETF position peaked at $279K in Q2 2015.
196 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2015.

Based on Jacobs & Co's 13F filing for Q3 2015, filed 15 Oct 2015.